TORONTO, Ontario –  The utility of Rna Diagnostics’ RDA™ (Rna Disruption Assay) test in assessing the effect of chemotherapy drugs has been further illustrated in research just published by Toronto biopharma company Armour Therapeutics. The study entitled, “Relaxin antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts”, was published in leading journal, Endocrine-Related Cancer.

Rna Diagnostics and Armour Therapeutics engaged in the research collaboration that led to these exciting findings.  Armour is developing a first-in-class anti-hormonal drug for the treatment of advanced prostate cancer, when tumors become resistant to conventional drugs that are designed to block the action of androgen hormones.  Rna Diagnostics has developed the RNA Disruption Assay™ (RDA™) which measures the responsiveness of cancers to chemotherapy.

One of the objectives of this study was to examine the mechanism behind the synergy of Armour’s lead compound AT-001, with docetaxel, which is the standard-of-care chemotherapy for the management of advanced prostate cancer. Rna Diagnostics’ RDA test was used to measure the level of RNA disruption in prostate cancer cells caused by docetaxel or a combination of docetaxel and AT-001.

“The RDA test played an instrumental role in demonstrating that AT-001 increased tumor responsiveness to the cytotoxic activity of docetaxel”, said Dr. Josh Silvertown, CEO of Armour Therapeutics. “Ultimately, the RDA test could offer the potential for clinicians to ascertain early whether the dosing regimen of AT-001 and docetaxel is effective or not in patients”.

“This study clearly shows the promise of RDA to be of diagnostic value in demonstrating response to therapy in cancers such as prostate cancer”, said Dr. Ken Pritzker, CEO of Rna Diagnostics. “It also provides evidence that RDA is a useful test in drug development to assess response to therapy and evidence that RDA is useful as a therapy response biomarker for hormone responsive tumours.

About Rna Diagnostics
Rna Diagnostics is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RNA Disruption Assay™ (RDA™), determines early in a woman’s breast cancer treatment whether she is responding to the chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy and thereby improving her outcome. For more information on Rna Diagnostics, please visit

About Armour Therapeutics Inc.
Armour Therapeutics Inc. is a biopharmaceutical company leading the development of first-in-class anti-hormone therapeutics for the treatment of reproductive-tissue-based cancers. Armour’s lead compound, AT-001, developed at the University Health Network and Ontario Cancer Institute in Toronto, is a non-androgen, anti-hormone therapy being developed for patients with hormone-refractory prostate cancer. Armour is also developing its AT-012 and AT-027 programs targeting breast and ovarian cancers, respectively. Privately-held Armour Therapeutics is based in Toronto, Ontario, Canada.